PPARs: Regulators of Metabolism and As Therapeutic Targets in Cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ
2017; Future Medicine; Volume: 13; Issue: 3 Linguagem: Inglês
10.2217/fca-2017-0019
ISSN1744-8298
AutoresLu Han, Wen‐Jun Shen, Stefanie Bittner, Fredric B. Kraemer, Salman Azhar,
Tópico(s)Metabolism, Diabetes, and Cancer
ResumoThe PPARs are a subfamily of three ligand-inducible transcription factors, which belong to the superfamily of nuclear hormone receptors. In mammals, the PPAR subfamily consists of three members: PPAR-α, PPAR-β/δ and PPAR-γ. PPARs control the expression of a large number of genes involved in metabolic homeostasis, lipid, glucose and energy metabolism, adipogenesis and inflammation. PPARs regulate a large number of metabolic pathways that are implicated in the pathogenesis of metabolic diseases such as metabolic syndrome, Type 2 diabetes mellitus, nonalcoholic fatty liver disease and cardiovascular disease. The aim of this review is to provide up-to-date information about the biochemical and metabolic actions of PPAR-β/δ and PPAR-γ, the therapeutic potential of their agonists currently under clinical development and the cardiovascular disease outcome of clinical trials of PPAR-γ agonists, pioglitazone and rosiglitazone.
Referência(s)